Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | PDE6D | O43924 | 1/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.86 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3201954 | 1.00 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3210158 | 1.00 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10297391 | 1.00 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL5316885 | 1.00 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3198400 | 1.00 | HMGCR (0.86) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL5287899 | 0.96 | HMGCR (0.80) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4170869 | 0.93 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL2520 | 0.93 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4209321 | 0.93 | HMGCR (0.78) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 0.93 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8394956-B2 | Process for preparing pyrimidine propenaldehyde | AUROBINDO PHARMA LTD. (IN) | 2013-03-12 | — | — | US | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| US-8318933-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD (IN) | 2012-11-27 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8212034-B2 | Process for preparing rosuvastatin calcium | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | MALLELA SAMBHU PRASAD SARMA | 2011-07-21 | — | — | US | disclosed |
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-25 | — | — | US | disclosed |
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LTD (IN) | 2010-02-25 | — | — | US | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
| WO-2008096257-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
| US-20080161560-A1 | Process for Preparation of Calcium Salt of Rosuvastatin | DESHPANDE PANDURANG BALWANT | 2008-07-03 | — | — | US | disclosed |
| WO-2008053334-A2 | AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| EP-1869005-A1 | PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2007-12-26 | — | — | EP | disclosed |
| EP-1863773-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006106526-A1 | PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006100689-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048899-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CACNA1I, CACNA1S, CACNA1F | HMGCR 17/4885ALDH1A1 2957/4885CYP3A4 117/4885 |
| US-20110178296-A1 | Process for preparing pyrimidine propenaldehyde | DPYD, NOX4, RPIA | HMGCR 5/4885ALDH1A1 36/4885CYP3A4 63/4885 |
| US-20080161560-A1 | Process for Preparation of Calcium Salt of Rosuvastatin | CACNA1C, CACNA1E, CACNA1S | HMGCR 16/4885ALDH1A1 2901/4885CYP3A4 583/4885 |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | ACSL5, HMGCR, PCSK9 | HMGCR 2/4885ALDH1A1 1776/4885CYP3A4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.